


Scienceure Holdings, Inc. (SCNX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001382574

Scienceure Holdings, Inc. SCNX; healthcare	
Grade	D  fourth fifth of 371 graded peers percentile 69.7; sampling error 2.5 points; lower is stronger
Rank	259 of 371
Profitability	D  percentile 68.3
Solvency	C  percentile 48.8
Growth and financing	C  percentile 49.0
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$84.2M
Standard universe	outside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: dilution, distress
Inputs computable	7 of 14
Graded from	filings received through Apr 30, 2026 162 days before the rescans; latest periodic filing 10-Q received Aug 13, 2026
Last close	\$3.85 2026-10-08; market equity \$158.1M
Price used in grade	None

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

Information included in this Annual Report should be read in conjunction with the consolidated financial statements and related notes in "Item 8. Financial Statements and Supplemental Data" of this Annual Report. logo and some of our trademarks and tradenames are used in this Annual Report. This Annual Report may also include trademarks, tradenames and service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this Annual Report may appear without the ®.

? and SM symbols.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 68.3						
Gross profitability		0.4%	32.2%	91.9	372	2025-12-31
Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(29.8%)	(6.6%)	14.7	811	2025-12-31
Gross margin stability, five years		28.9 pts	2.8 pts	98.3	243	2025-12-31
Solvency, sleeve percentile 48.8						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(0.88)	(0.31)	40.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.89x	2.96x	57.0	839	2025-12-31
Growth and financing, sleeve percentile 49.0						
Revenue growth, three-year compound		(65.2%)	10.0%	97.6	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 2
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		183.1%	2.1%	0.4	704	2025-12-31
Net share issuance, one year		not computable	2.5%			prior share count is 34 days earlier

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 2,646,694 USD; Altman Z is not used



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
254	Orchestra BioMed Holdings, Inc. (OBIO)	68.4	D	dilution, short runway, fortress balance sheet
255	Adaptive Biotechnologies Corp. (ADPT)	68.6	D	
256	Iridex Corp. (IRIX)	68.9	D	fortress balance sheet
257	Lyell Immunopharma, Inc. (LYEL)	69.2	D	dilution, degenerate inputs
258	Iovance Biotherapeutics, Inc. (IOVA)	69.5	D	dilution, short runway
259	Scienture Holdings, Inc. (SCNX) <	69.7	D	fortress balance sheet
260	Rockwell Medical, Inc. (RMTI)	70.0	D	
261	Bioventus Inc. (BVS)	70.3	D	
262	Ovid Therapeutics Inc. (OVID)	70.5	D	dilution, short runway
263	uniQure N.V. (QURE)	70.8	D	fortress balance sheet
264	Regeneron Pharmaceuticals, Inc. (REGN)	71.1	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(54.3%)	8.0%	12
Distance from 52-week high	(44.3%)	(31.4%)	33
EBIT to enterprise value	(28.0%)	(1.5%)	20
Free cash flow yield	(9.0%)	(1.0%)	32
Book value to price	0.40	0.28	62
Sales to price	0.00	0.31	4
Composite equity issuance, five years	385.9%	20.3%	97
Relative strength against the sector, log excess return	(0.99)	(0.14)	12

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass

Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$8.2M
Operating cash flow, four quarters	-\$14.4M
Months of runway	6.8
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$128,041

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$331,482	2025-12-31	2026-03-30	10-K	0001493152-26-013475
2	assets	us-gaap:Assets	\$84.2M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
3	net income	us-gaap:NetIncomeLoss	-\$41.5M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$13.4M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
5	assets	us-gaap:Assets	\$104.9M	2024-12-31	2026-03-30	10-K	0001493152-26-013475
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$431,609	2025-12-31	2026-03-30	10-K	0001493152-26-013475
7	gross profit	us-gaap:GrossProfit	\$6,005	2024-12-31	2026-03-30	10-K	0001493152-26-013475
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$136,643	2024-12-31	2026-03-30	10-K	0001493152-26-013475
9	gross profit	us-gaap:GrossProfit	\$49,030	2023-12-31	2025-03-26	10-K	0001641172-25-000657
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.4M	2023-12-31	2025-03-26	10-K	0001641172-25-000657
11	gross profit	us-gaap:GrossProfit	\$5.5M	2022-12-31	2024-04-22	10-K	0001493152-24-015595
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.3M	2022-12-31	2024-04-22	10-K	0001493152-24-015595
13	gross profit	us-gaap:GrossProfit	\$4.7M	2021-12-31	2023-03-27	10-K	0001493152-23-009090
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9.9M	2021-12-31	2023-03-27	10-K	0001493152-23-009090
15	current assets	us-gaap:AssetsCurrent	\$7.9M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
16	current liabilities	us-gaap:LiabilitiesCurrent	\$2.7M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$80.6M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
18	operating income	us-gaap:OperatingIncomeLoss	-\$42.6M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
19	book equity	us-gaap:StockholdersEquity	\$70.1M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
20	liabilities	us-gaap:Liabilities	\$14.1M	2025-12-31	2026-03-30	10-K	0001493152-26-013475
21	total debt	us-gaap:LongTermDebt	\$225,000	2019-12-31	2020-03-30	10-K	0001493152-20-005026
22	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$2.9M	2019-12-31	2021-03-29	10-K	0001493152-21-007052
23	operating income	us-gaap:OperatingIncomeLoss	\$125,224	2019-12-31	2021-03-29	10-K	0001493152-21-007052
24	depreciation amortization	us-gaap:Depreciation	\$5,000	2019-12-31	2021-03-29	10-K	0001493152-21-007052
25	operating income	us-gaap:OperatingIncomeLoss	-\$4.4M	2023-12-31	2025-03-26	10-K	0001641172-25-000657
26	interest expense	us-gaap:InterestExpense	\$1.2M	2023-12-31	2024-04-22	10-K	0001493152-24-015595
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$12,000	2024-12-31	2026-03-30	10-K	0001493152-26-013475
28	depreciation amortization	us-gaap:Depreciation	\$2,000	2024-12-31	2026-03-30	10-K	0001493152-26-013475
29	operating income	us-gaap:OperatingIncomeLoss	-\$14.7M	2024-12-31	2026-03-30	10-K	0001493152-26-013475
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$18.6M	2023-12-31	2026-03-30	10-K	0001493152-26-013475
31	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$534,396	2024-12-31	2026-03-30	10-K	0001493152-26-013475
32	current assets	us-gaap:AssetsCurrent	\$6.3M	2024-12-31	2026-03-30	10-K	0001493152-26-013475
33	current liabilities	us-gaap:LiabilitiesCurrent	\$7.9M	2024-12-31	2026-03-30	10-K	0001493152-26-013475
34	current assets	us-gaap:AssetsCurrent	\$2.8M	2023-12-31	2025-03-26	10-K	0001641172-25-000657
35	current liabilities	us-gaap:LiabilitiesCurrent	\$11.6M	2023-12-31	2025-03-26	10-K	0001641172-25-000657
36	assets	us-gaap:Assets	\$12.5M	2023-12-31	2025-03-26	10-K	0001641172-25-000657
37	assets	us-gaap:Assets	\$3.7M	2022-12-31	2024-04-22	10-K	0001493152-24-015595
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,630,815	2026-04-30	2026-04-30	10-K/A	0001493152-26-020707
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,630,815	2026-03-27	2026-03-30	10-K	0001493152-26-013475